A Phase I Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Napabucasin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sumitomo Dainippon Pharma
- 06 Mar 2017 Planned End Date changed from 1 May 2016 to 1 Nov 2016.
- 06 Mar 2017 Planned primary completion date changed from 1 May 2017 to 1 Nov 2017.
- 06 Mar 2017 Status changed from recruiting to active, no longer recruiting.